Cystic Fibrosis Weekly Update

Contents:

Can We Talk About CF Pain?

Aug 23, 2019 09:00 am | Elizabeth Rogers

We need to talk about pain. Growing up, there was a clear delineation in my mind: Cystic fibrosis (CF) could be painful sometimes, but it wasn’t a disease that caused constant pain. It was almost a mantra in my mind: “At least I’m not always in pain.” Or, “It could be worse; I could be […]
The post Can We Talk About CF Pain? appeared first on Cystic Fibrosis News Today.

Path BioAnalytics Acquires Cavosonstat From Laurel Therapeutics for Further Study

Aug 23, 2019 07:00 am | Marisa Wexler MS

Path BioAnalytics (PBA), a biotechnology company based in North Carolina, has licensed the rights to further develop cavosonstat (N91115), a targeted therapy for cystic fibrosis (CF), from the Chinese company Laurel Therapeutics. Cavosonstat is a small molecule designed to increase the stability of the CFTR protein, defects of which cause CF. The CFTR modulator works by blocking the enzyme S-nitrosoglutathione reductase […]
The post Path BioAnalytics Acquires Cavosonstat From Laurel Therapeutics for Further Studyappeared first on Cystic Fibrosis News Today.

Cellular Metabolism Defect May Cause Pseudomonas Lung Infections in CF Patients, Study Says

Aug 22, 2019 08:00 am | Joana Carvalho, MSc

A defect in cellular metabolism is the root cause for the high incidence of lung infections caused by the bacteria Pseudomonas aeruginosa in patients with cystic fibrosis (CF), a study has found. Results from the study, “CFTR-PTEN–dependent mitochondrial metabolic dysfunction promotes Pseudomonas aeruginosa airway infection,” were published in the journal Science Translational Medicine. CF is a genetic […]
The post Cellular Metabolism Defect May Cause Pseudomonas Lung Infections in CF Patients, Study Says appeared first on Cystic Fibrosis News Today.